On January 21, 2026, AEON Biopharma, Inc. exchanged $15 million in convertible notes with Daewoong Pharmaceutical for nearly 12 million shares of common stock and issued additional warrants. The event was significant as it involved substantial equity and corporate governance decisions, including voting approval on the 2023 Incentive Award Plan.